Last reviewed · How we verify
Rotigotine Nasal Spray
At a glance
| Generic name | Rotigotine Nasal Spray |
|---|---|
| Also known as | SPM937, Neupro, SPM 952 |
| Sponsor | UCB Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms (PHASE2)
- Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rotigotine Nasal Spray CI brief — competitive landscape report
- Rotigotine Nasal Spray updates RSS · CI watch RSS
- UCB Pharma portfolio CI